**[Reply Form\_** **Curriculum Vitae]**

|  |  |  |
| --- | --- | --- |
| **Name** | **Seok Jin KIM** |  |
| **Affiliation** | Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine |
| **Official Position** | Professor |
| **Education** | |  |  | | --- | --- | | 1988. 3 – 1994. 2 | Bachelor’s degree, College of Medicine, Korea University, Seoul, Korea | | 1995. 9 – 1997. 8 | Master’s degree, Graduate School of Korea University, Seoul, Korea | | 1997. 9 – 2003. 2 | Ph.D., Graduate School of Korea University, Seoul, Korea | | |
| **Major Career**  **(less than**  **5 items)** | |  |  | | --- | --- | | 1995. 3 – 1999. 2 | Residency of Internal medicine, Korea University Anam Hospital, Seoul, Korea | | 2002. 4 – 2003. 4 | Fellowship of Hematology/Oncology, Korea University Medical Center, Seoul, Korea | | 2003. 5 – 2004. 8 | Postdoctoral fellow, Medicine-Oncology, Duke University Medical Center, NC, USA | | 2004. 9 – 2008. 1 | Assistant professor, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea | | 2008. 2 – 2014. 3 | Associate professor, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea | | 2014. 4 - | Professor, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea | | |
| **Biography**  Professor Seok Jin Kim is Staff Specialist Hematologist, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea. He has had a career long clinical, laboratory and academic interest in non-Hodgkin lymphoma (NHL), especially, T and NK-cell lymphoma and diffuse large B-cell lymphoma. He is an active member of the Korean Lymphoma Working Party and Consortium for Improving Survival of Lymphoma (CISL). He has been Principal Investigator (PI) for numerous national and international clinical trials for NHL. He is now conducting phase II trials for patients with T-cell and NK/T-cell lymphomas using immune checkpoint inhibitors and immunomodulatory drugs. His main translational research interest is the development of biomarkers predicting the outcome of patients with NHL using liquid biopsy samples including cell-free tumor DNA and exosomes. | | |

\* Please note that your Reply Form & Photo might be uploaded at KAI International Meeting 2020 website.